Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...
Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide ...
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third most common cause of cancer mortality. Its incidence is increasing worldwide because of the dissemination of ...
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
Oclaiz is a subcutaneous long-acting octreotid depot, designed for optimized disease control and convenient self-administration. The product is based on Camurus' FluidCrystal technology and is ...
Please provide your email address to receive an email when new articles are posted on . Most adults with acromegaly maintained or improved IGF-I levels with oral octreotide in three phase 3 trials.
CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...
PRESS RELEASE: Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
Company Plans to Initiate Phase III Program in First Half of 2008 LEXINGTON, Mass., Nov. 28 -- Indevus Pharmaceuticals, Inc. today announced positive results from its Phase II octreotide implant trial ...
Syringe and Vials To date, the Company has not received any reports of adverse reactions related to this recall. Mylan Institutional LLC, a Viatris Company, has voluntarily recalled 1 lot of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback